Adolescent girls and young women are disproportionately affected by HIV in sub-Saharan Africa where they are up to 8 times more likely to be infected compared to their male counterparts.

A major biological mechanism driving this increased risk is subclinical genital inflammation due to the presence of “non-optimal” vaginal microbiota depleted of beneficial lactobacillus species.

This study will formulate and perform preclinical safety studies of an anti-inflammatory microbiota metabolite for in-vivo evaluation.

Timeline

2019